Vyas Rahul, Jain Shubhika, Thakre Anuj, Thotamgari Sahith Reddy, Raina Sameer, Brar Vijaywant, Sengupta Partho, Agrawal Pratik
Department of Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA.
Division of Cardiology, Department of Medicine, Louisiana State University Health Sciences Center, Ochsner-LSU Health, Shreveport, Louisiana, USA.
J Cardiovasc Electrophysiol. 2024 Dec;35(12):2474-2482. doi: 10.1111/jce.16451. Epub 2024 Oct 3.
Atrial fibrillation (Afib) is a prevalent chronic arrhythmia associated with severe complications, including stroke, heart failure, and increased mortality. This review explores the use of smartwatches for Afib detection, addressing the limitations of current monitoring methods and emphasizing the potential of wearable technology in revolutionizing healthcare.
RESULTS/OBSERVATION: Current Afib detection methods, such as electrocardiography, have limitations in sensitivity and specificity. Smartwatches with advanced sensors offer continuous monitoring, improving the chances of detecting asymptomatic and paroxysmal Afib. The review meticulously examines major clinical trials studying Afib detection using smartwatches, including the landmark Apple Heart Study and ongoing trials such as the Heart Watch, Heartline, and Fitbit Heart Study. Detailed summaries of participant numbers, smartwatch devices used, and key findings are presented. It also comments on the cost-effectiveness and scalability of smartwatch-based screening, highlighting the potential to reduce healthcare costs and improve patient outcomes.
CONCLUSION/RELEVANCE: The integration of wearable technology into healthcare can lead to earlier diagnosis, improved patient engagement, and enhanced cardiac health monitoring. Despite ethical considerations and disparities, the potential benefits outweigh the challenges. This review calls for increased awareness, collaboration with insurance companies, and ongoing research efforts to optimize smartwatch accuracy and encourage widespread adoption of Afib detection. With insights from major trials, this review serves as a comprehensive reference for healthcare professionals and policymakers, guiding future strategies in the early diagnosis and management of atrial fibrillation.
心房颤动（房颤）是一种常见的慢性心律失常，与包括中风、心力衰竭和死亡率增加在内的严重并发症相关。本综述探讨了智能手表在房颤检测中的应用，阐述了当前监测方法的局限性，并强调了可穿戴技术在变革医疗保健方面的潜力。
结果/观察：目前的房颤检测方法，如心电图，在敏感性和特异性方面存在局限性。配备先进传感器的智能手表可提供连续监测，提高检测无症状和阵发性房颤的几率。该综述精心审视了使用智能手表进行房颤检测的主要临床试验，包括具有里程碑意义的苹果心脏研究以及正在进行的试验，如心脏手表研究、心脏线研究和Fitbit心脏研究。文中呈现了参与者数量、所使用的智能手表设备以及主要研究结果的详细总结。它还对基于智能手表的筛查的成本效益和可扩展性进行了评论，强调了降低医疗成本和改善患者预后的潜力。
结论/意义：将可穿戴技术整合到医疗保健中可实现更早的诊断、提高患者参与度并加强心脏健康监测。尽管存在伦理考量和差异，但潜在益处大于挑战。本综述呼吁提高认识、与保险公司合作以及持续开展研究工作，以优化智能手表的准确性并鼓励广泛采用房颤检测。基于主要试验的见解，本综述为医疗保健专业人员和政策制定者提供了全面的参考，指导房颤早期诊断和管理的未来策略。
